Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07806851) titled 'UBT251 Injection Phase ? Study (OSA-PAP)' on Sept. 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: The United Bio-Technology (Hengqin) Co., Ltd.

Condition: Obstructive Sleep Apnea Obesity

Intervention: Drug: UBT251 Drug: UBT251

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: October 10, 2026

Target Sample Size: 150

To know more, visit https://clinicaltrials.gov/study/NCT07806851

Disclaimer: Curated by HT Syndication....